Keytruda/Lenvima combo shows promise in hard-to-treat cancers
Data shows a range of responses in different tumours
Read More
Tag: ESMO
Tecentriq combo proves effective in bladder cancer
The drug improved progression-free survival to 8.2 months from 6.3 months.
Read More
Zejula successful in advanced ovarian cancer
GlaxoSmithKline presented the results at the ESMO Congress.
Read More
Novartis announces positive asthma results
Marketing applications for the treatments are currently being reviewed by the EMA.
Read More
Continued success for Lynparza in ovarian cancer
The drug improved progression-free survival time to a median of 22.1 months, compared to 16.6 months.
Read More
Lynparza bags positive prostate cancer results
The drug more than doubled median radiographic progression-free survival.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
